

HEMAGENETICS TECHNOLOGIES CORP.

NOTICE OF CHANGE IN CORPORATE STRUCTURE

National Instrument 51-102 – Section 4.9

Item 1 – Names of the parties to the transaction

HemaGenetics Technologies Corp. (“HGT”)
Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.) (“MCR”)
1169029 B.C. Ltd. (“029”)
1169032 B.C. Ltd. (“032”)
1169071 B.C. Ltd. (“071”)
1169077 B.C. Ltd. (“077”)
1169082 B.C. Ltd. (“082”)

Item 2 – Description of the transaction

On June 26, 2018, HGT, MCR, 029, 032, 071, 077, and 082 entered into an arrangement agreement, pursuant to which HGT would spinout each of the other parties as HGT’s subsidiaries into separate entities (the “Arrangement”). The Arrangement received HGT Shareholder approval on June 26, 2018 and final court approval from the British Columbia Supreme Court under Part 9, Division 5 of the Business Corporations Act (British Columbia) on July 19, 2018. Under the Arrangement, the effective date for the Arrangement can be set separately as between HGT and each of the other parties to the Arrangement. Pursuant to the Arrangement, the effective date for the Arrangement with 082 was set for April 29, 2019 and 082 became a reporting issuer in British Columbia and Alberta. Under the Arrangement, HGT transfers \$1,000 cash and a letter of intent dated June 18, 2018 between HGT & 1168569 B.C. Ltd. to 082 in exchange for the issuance of 8,502,104 common shares of 082 issued to HGT’s shareholders of record as of October 15, 2018, on a pro rata basis, pursuant to the Arrangement. The Arrangement involved the deemed exchange of HGT shares held by HGT shareholders of record with 082 common shares, which share exchange occurred pursuant to the Arrangement effective on April 29, 2019.

082’s financial year end is May 31st.

Item 3 – Effective Date of the transaction

April 29, 2019.

Item 4 – Names of each party, if any, that ceased to be a reporting issuer subsequent to the transaction and name of the continuing entities

No party ceased to be a reporting issuer subsequent to the Arrangement. As a result of the Arrangement, 082 became a reporting issuer in the provinces of Alberta and British Columbia on the Effective Date.

Item 5 – The date of the reporting issuer’s first financial year-end after the transaction.

HGT: November 30, 2019

082: May 31, 2019

Item 6 – The periods, including the comparative periods, if any, of the interim and annual financial statements required to be filed for the reporting issuer’s first financial year after the Arrangement

HGT: HGT’s first audited annual financial statements after the effective date of the transaction will be for the year ending November 30, 2019. HGT’s first interim financial statements after the effective date of the transaction will be for the six month interim period ending May 31, 2019, and the nine month interim period ending August 31, 2019.

082: 082’s first audited annual financial statements after becoming a reporting issuer will be for the period ending May 31, 2019.

Item 7 – Documents filed that describe the Transaction and where those documents can be found in electronic format.

Unless noted otherwise, all of the following are posted on HGT’s SEDAR profile accessible at www.sedar.com:

- News release of HGT dated April 29, 2019
- Material Change Report of HGT dated April 29, 2019
- Notice of change in corporate structure of 082 dated April 29, 2019 (posted on 082’s SEDAR profile at www.sedar.com)
- News release of 082 dated April 29, 2019 (posted on 082’s SEDAR profile at www.sedar.com)
- Material Change Report of 082 dated April 29, 2019 (posted on 082’s SEDAR profile at www.sedar.com)
- News release of HGT posted on April 26, 2019
- The arrangement agreement posted on October 10, 2018

Item 8 – Date of Report

April 29, 2019.

HemaGenetics Technologies Corp.

Per:



Ron Ozols, Director, CFO, V.P. Communications